Abstract:Abstract Metabolic reprogramming has now been well recognized as one of 10 hallmarks of cancer. The plasma membrane transporters, that enable efficient cellular metabolism and aid in nutrient sensing, are receiving increasing attention in recent years. Membrane transporters include 3 main classes: ABC transporters, p-type ATPases, and the solute carrier family (SLC). The SLC group of transporters includes nearly 400 members organized into 52 families that mediate the transport of a wide variety of substrates across biological membranes. Until recently, little was known about the role of these SLC transporters in the mechanisms of cancer development and progression. Yet, the genomic landscape and clinical relevance of SLC transporters in human cancer have not been investigated systematically. We here performed a comprehensive characterization of 396 SLC transporters by integrating multi-platform data across over 30 tumor types from The Cancer Genome Atlas. We observed frequent dysregulation of SLC transporters across cancer types and identified cancer type- and subtype-specific expression signatures. We identified significant correlations of these SLC transporters with the activity of cancer metabolic pathways and explored their complex regulatory networks. We also investigated the role of SLC transporters in tumor metastasis. We further evaluated the potential clinical relevance of these SLC transporters and identified multiple SLC transporters that were significantly associated with patients' clinical outcomes. Our study provided an in-depth understanding of the role of SLC transporters in cancer metabolic reprogramming, elucidated their mechanisms in cancer development and metastasis, and provided novel biomarkers and potential therapeutic targets that can be further developed for future clinical applications. Citation Format: Ruiping Wang, Shaojun Zhang, Andy Futreal, Linghua Wang. Comprehensive characterization of the SLC transporters in human cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2018;78(13 Suppl):Abstract nr 3489.

The genetic interaction map of the human solute carrier superfamily

The solute carrier superfamily interactome

Metabolic mapping of the human solute carrier superfamily

Data- and knowledge-derived functional landscape of human solute carriers

Analysis and update of the human solute carrier (SLC) gene superfamily

A widespread role for SLC transmembrane transporters in resistance to cytotoxic drugs

The full spectrum of SLC22 OCT1 mutations illuminates the bridge between drug transporter biophysics and pharmacogenomics

Combinatorial GxGxE CRISPR screen identifies SLC25A39 in mitochondrial glutathione transport linking iron homeostasis to OXPHOS

The SLC transporter in nutrient and metabolic sensing, regulation, and drug development

Defining solute carrier transporter signatures of murine immune cell subsets

Predicting substrates for orphan Solute Carrier Proteins using multi-omics datasets

The Solute Carrier Transporters and the Brain: Physiological and Pharmacological Implications.

In silico analysis of the solute carrier (SLC) family in cancer indicates a link among DNA methylation, metabolic adaptation, drug response, and immune reactivity

The Functional Impact of SLC6 Transporter Genetic Variation

Abstract 3489: Comprehensive Characterization of the SLC Transporters in Human Cancer

The mitochondrial transporter family (SLC25): physiological and pathological implications

The full spectrum of OCT1 (SLC22A1) mutations bridges transporter biophysics to drug pharmacogenomics

Human transporter database: comprehensive knowledge and discovery tools in the human transporter genes.

Novel drug transporter substrates identification: An innovative approach based on metabolomic profiling, in silico ligand screening and biological validation

ProteoMutaMetrics: machine learning approaches for solute carrier family 6 mutation pathogenicity prediction

Solute carrier transporters: the metabolic gatekeepers of immune cells